The Lancet Haematology in conversation with

Bethany Samuelson Bannow and Maureen Achebe on classical haematological disease in women Aug 6, 2026 1468 Dr Lan-Lan Smith joined the lead author of our latest Commission Dr Bethany Samuelson Bannow and author Dr Maureen Achebe to discuss classical haematological disease in women with Dr Julia Sandrin Gauer from the Intenational Society on Thrombosis and Haemostasis. The podcast was recorded and produced by the ISTH to coincide with the launch of the Commission at the ISTH congress in Paris in July 20

Fabio Efficace and Alice Di Rocco on patient-reported outcomes following CAR T-cell therapy Jul 3, 2026 955 Most previous patient-reported outcome results for CAR T-cell therapy have come from clinical trials testing these treatments, but information on how patients experience this treatment in real-world settings is scarce. Dr Fabio Efficace and Dr Alice Di Rocco discuss their recent prospective study to measure real-world patient-reported symtomatic adverse events in those receiving CAR T-cell therap

Carmelo Gurnari on the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee Jun 4, 2026 1025 Dr Carmelo Gurnari joins us to discuss the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee on diagnosis, prevention, treatment, and donor management of donor cell-derived haematological neoplasms after HCT click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00046-3/fulltext The Lancet Haematology in co

Penelope Stein on acute prophyria Apr 28, 2026 961 Dr Penelope Stein joins us to discuss the development of new international guidelines for the diagnosis, management, and treatment of the rare, genetically-linked condition, acute prophyria. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00044-X/fulltext The Lancet Haematology in conversation with... is part of the Lancet Group podcast offe

Marc Riedl on hereditary angioedema Apr 2, 2026 1050 Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks. Click here to read the full articles: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext https://www.thelancet.com/journals/

Julio Delgado and Valentín Ortiz-Maldonado (Spanish version) Mar 5, 2026 775 Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext English version of this podcast: https://www.

Julio Delgado and Valentín Ortiz-Maldonado Mar 5, 2026 724 Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext Continue this conversation on social! Follow

Erica Kaye and Dylan Graetz discuss expert recommendations for the conduct and appraisal of qualitative research in haematology Feb 5, 2026 1180 Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions, and promote the patient voice. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00321-7/fulltext Continue this conversation

Presented at ASH: API-CAT post-hoc analysis on predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE Jan 1, 2026 595 Professor Isabelle Mahé joins us to discuss the results of a post-hoc analysis of the API-CAT trial identifying predictors associated with clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00291-1/fulltext Continue this conversation on soc

Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation Dec 9, 2025 862 Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.

ASH 2025 Preview - Expert Roundtable Dec 3, 2025 1332 Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/t

Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia Dec 2, 2025 1464 Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltext Cont

$Ruben Mesa on ropeginterferon alfa-2b for hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia$

Ruben Mesa on ropeginterferon alfa-2b for hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia Nov 3, 2025 705 Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at...

A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas Sep 15, 2025 1078 Today, on World Lymphoma Awareness Day, Professors Yok Lam Kwong, Wee Joo Chng, and Eric Tse join us in this joint episode of The Lancet Haematology and The Lancet Regional Health - Western Pacific to discuss their recent Series on advances in genomic techniques that have transformed the diagnosis, prognosis, and targeted treatment of mature T-cell and natural killer-cell lymphoma. Read the Series

Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences Aug 5, 2025 1150 June has been packed with interesting haematology conferences so the editorial team behind The Lancet Haematology have gathered to share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis meetings. Read our conference round-ups here: EHA: https://www.thelance

$Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lympho...$

Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lympho... Jul 2, 2025 1309 Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-c

A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies Jun 13, 2025 2411 With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care. R

Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma Apr 29, 2025 949 Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma. Read the full article: https://www.thelancet.com/jour

Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia Apr 1, 2025 1067 Dr Romy Pothof and Prof Joanne Verweij join us to discuss their development of an international consensus on the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00029-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... h

Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe Mar 4, 2025 1626 Prof Helene Schoemans, Elke Stienissen, and Kathy Goris join us to discuss the importance of consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet

Dawn Swan on air pollution and venous thromboembolism Jan 29, 2025 902 Dr Dawn Swan joins us to discuss current knowledge and future perspectives on the possible association between air pollution and venous thromboembolism. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00291-6/fulltext?dgcid=buzzsprout_icw_podcast_general_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ http

Leslie Skeith on low-dose aspirin for postpartum venous thromboembolism prophylaxis Jan 17, 2025 963 Dr Leslie Skeith joins us to discuss the PARTUM pilot trial, comparing low-dose aspirin versus placebo in postpartum venous thromboembolism. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00338-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagra

Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom Dec 4, 2024 1073 Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation outcomes in the United Kingdom. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00312-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this co

Lancet Haematology 10 year anniversary - meet the editors Oct 2, 2024 2841 In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights into the editorial processes at The Lancet Group. Read our Editorial: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00289-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Con

Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome Aug 23, 2024 488 Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://

Kim Linton on follicular lymphoma Aug 7, 2024 588 Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00166-2?dgcid=buzzsprout_tlv_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet

Judy Truong on ferritin reference levels and iron deficiency Aug 5, 2024 677 Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising propagation of related health inequity and social injustice in medicine. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00103-0?dgcid=buzzsprout_tlv_podcast_ge

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML Jul 16, 2024 851 Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_

Banu Aygun on sickle cell anaemia May 24, 2024 673 Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00078-4?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://in

Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia Mar 1, 2024 1086 Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00030-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/th

Elisabeth Schorb on the MARTA phase 2 trial Feb 29, 2024 563 Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00371-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on soc

Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies Feb 1, 2024 783 Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagra

Dr Sarah O’Brien on the PREVAPIX-ALL trial Dec 20, 2023 830 Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00314-9/fulltex

Enrico Lopriore on haemolytic disease of the fetus and newborn Nov 29, 2023 753 Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00285-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.b

$Meletios Dimopoulos on relapsed and refractory multiple myeloma$

Meletios Dimopoulos on relapsed and refractory multiple myeloma Oct 3, 2023 660 Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on so

Eric Ohuma on haemoglobin concentrations and neonatal outcomes Aug 30, 2023 987 Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at

Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding Aug 1, 2023 793 Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-302

Oreofe Odejide and Thomas Kuczmarski on mental health and lymphoma Jul 4, 2023 992 Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social!

Alok Srivastava on fitusiran for patients with haemophilia A and B Mar 29, 2023 1121 Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B. Read the two trials: Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH) https://www.thelancet.com/journals/lancet/article/PIIS0140-673

Emmanuela E Ambrose on stroke prevention in children with sickle cell disease Mar 2, 2023 691 Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania Read the full article: Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE) Continue this conversation on social! Follow us today at... https://thelancet.bsky.soc

Sumit Gupta on racial and ethnic disparities in leukaemia survival outcomes Jan 31, 2023 1330 Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia. Read the full article: Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebo

Xiao-Jun Huang on cellular therapy in China Nov 29, 2022 1690 Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China. Read the Series papers: Cellular therapy in China Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com

Glenn Pierce on haemophilia care in LMICs Aug 31, 2022 2095 Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries. Read the full Review: Achieving access to haemophilia care in low-income and lower-middle-income countries Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/

Amy DeZern on the link between myelodysplastic syndrome and autoimmune disorders Jun 30, 2022 770 Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both. Read the full article: Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/

Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline Mar 7, 2022 905 Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/th

Fredrik Schjesvold on OCEAN phase 3 Feb 1, 2022 744 Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide. Read the full article: Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN) Continue this conversation on social! Follow us today at... https://thela

Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia Nov 25, 2021 719 Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext Continue this conversation on social! Follow us today a

Raul Cordoba on haematological malignancies in older people Nov 4, 2021 984 Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people. Read the full article: A comprehensive approach to therapy of haematological malignancies in older patients Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://

Obiageli Nnodu and Dennis Chao on child mortality from sickle cell disease in Nigeria Sep 21, 2021 543 Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00191-5/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/

Zuguo Mei and Gary Brittenham on iron deficiency Jul 28, 2021 514 Senior Assistant Editor Ben Burwood speaks with Dr Zuguo Mei (Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA) and Dr Gary M Brittenham (Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA) about their work defini

Eugenia Trigoso Arjona (in English) on nursing and haematological care May 12, 2021 1714 To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care. Continue this conversation on social! Follow us today at... h

Eugenia Trigoso Arjona (in Spanish) on nursing and haematological care May 12, 2021 1751 Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología. Continue this conversation on social! Follow us to

Nada Hamad on inclusion and diversity in haematology Feb 24, 2021 1802 A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet http

Dr Judith Boer on lymphoblastic leukaemia in children Dec 23, 2020 624 Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30353-7/fulltext Continue this conversation on social! Follow

Episodes

Recommended